We are live on
!
Find out more
LCM
Laurion Capital Management Portfolio holdings
AUM
$2.29B
1-Year Est. Return
75.73%
This Fund
S&P 500
This Quarter
Est. Return
-12.52%
1 Year Est. Return
+75.73%
3 Year Est. Return
+162.63%
5 Year Est. Return
+130.38%
10 Year Est. Return
+388.8%
AUM
$6.47B
AUM Growth
-$1.7B
(-21%)
Cap. Flow
-$612M
Cap. Flow
% of AUM
-9.46%
Top 10 Holdings %
Top 10 Hldgs %
39.4%
Holding
758
New
244
Increased
84
Reduced
79
Closed
303
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lowe's Companies
LOW
|
+$69.4M |
| 2 |
Morgan Stanley
MS
|
+$50.7M |
| 3 |
Citigroup
C
|
+$50.1M |
| 4 |
Amazon
AMZN
|
+$49.8M |
| 5 |
Warner Bros
WBD
|
+$42.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
International Flavors & Fragrances
IFF
|
+$284M |
| 2 |
T-Mobile US
TMUS
|
+$161M |
| 3 |
Qualcomm
QCOM
|
+$151M |
| 4 |
Micron Technology
MU
|
+$149M |
| 5 |
Alibaba
BABA
|
+$144M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 11.55% |
| 2 | Communication Services | 6.92% |
| 3 | Consumer Discretionary | 5.57% |
| 4 | Utilities | 3.44% |
| 5 | Financials | 2.79% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
176
AdaptHealth
AHCO
$696M
| $4.36M | 0.07% |
241,497
-388,060
| -62% | -$6.3M |
|
177
Accenture
ACN
$109B
| $4.33M | 0.07% |
15,603
+14,126
| +956% | +$4.24M |
|
178
JPMorgan Chase
JPM
$956B
| $4.29M | 0.07% |
38,065
+34,092
| +858% | +$4.22M |
|
179
Vor Biopharma
VOR
$1.27B
| $4.26M | 0.07% |
42,865
| – | – |
|
|
ICVX
180
DELISTED
Icosavax, Inc. Common Stock
ICVX
| $4.25M | 0.07% |
742,354
| – | – |
|
|
EPZM
181
DELISTED
Epizyme, Inc
EPZM
| $4.24M | 0.07% |
+2,885,100
| New | +$2.12M |
|
182
Alphabet (Google) Class C
GOOG
$4.35T
| $4.14M | 0.06% |
+37,880
| New | +$4.48M |
|
183
PayPal
PYPL
$50.5B
| $4.11M | 0.06% |
+58,797
| New | +$5.1M |
|
184
PUT
FedEx
FDX
$76.9B
| $3.99M | 0.06% |
+17,600
| New | +$3.76M |
|
185
Dow Inc
DOW
$22.1B
| $3.97M | 0.06% |
+76,896
| New | +$4.92M |
|
186
lululemon athletica
LULU
$14.5B
| $3.94M | 0.06% |
14,467
| – | – |
|
|
MBAC.U
187
DELISTED
M3-Brigade Acquisition II Corp. Units, each consisting of one share of Class A common stock, and one-third of one redeemable warrant
MBAC.U
| $3.92M | 0.06% |
400,000
| – | – |
|
188
Oracle
ORCL
$435B
| $3.91M | 0.06% |
+56,003
| New | +$4.1M |
|
189
Aldeyra Therapeutics
ALDX
$91.1M
| $3.88M | 0.06% |
+971,781
| New | +$3.34M |
|
190
Lineage Cell Therapeutics
LCTX
$286M
| $3.83M | 0.06% |
+2,422,367
| New | +$3.19M |
|
191
Viking Therapeutics
VKTX
$4.02B
| $3.83M | 0.06% |
+1,323,809
| New | +$3.28M |
|
192
Pliant Therapeutics
PLRX
$64.4M
| $3.77M | 0.06% |
+470,601
| New | +$3.01M |
|
193
Ross Stores
ROST
$81.7B
| $3.68M | 0.06% |
+52,405
| New | +$4.67M |
|
194
PUT
Wynn Resorts
WYNN
$10.6B
| $3.33M | 0.05% |
+58,500
| New | +$3.87M |
|
195
Entegris
ENTG
$22B
| $3.24M | 0.05% |
35,142
+27,814
| +380% | +$3.01M |
|
196
GH Research
GHRS
$2.03B
| $3.14M | 0.05% |
314,930
| – | – |
|
197
UroGen Pharma
URGN
$2.26B
| $3.12M | 0.05% |
+380,600
| New | +$2.61M |
|
198
Scholar Rock
SRRK
$6.32B
| $3.09M | 0.05% |
+562,182
| New | +$4.04M |
|
199
Rallybio
RLYB
$88.2M
| $3.04M | 0.05% |
50,250
+250
| +0.5% | +$18.8K |
|
200
Arrowhead Research
ARWR
$12.5B
| $3M | 0.05% |
+85,128
| New | +$3.2M |
|
Similar funds
AFM
GCP
LCM
MAP
MA
NSAM
ABI
OCM
Laurion Capital Management's Q2 2022 Portfolio in Review
As of Q2 2022, Laurion Capital Management held 758 positions worth $6.47B, down 21% from $8.17B the previous quarter. Its ten largest holdings account for 39% of the portfolio.
Laurion Capital Management withdrew a net $612M in Q2 2022, closing 303 positions and reducing 79 holdings. Its most notable exit was International Flavors & Fragrances, an estimated $284M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 12% of assets, down from 13% a quarter earlier, followed by Communication Services and Consumer Discretionary.
Against the trend, Laurion Capital Management opened a new position in Morgan Stanley worth $47M.
- Laurion Capital Management's largest Q2 2022 buy was Morgan Stanley: 618,580 shares worth $47M.
- Laurion Capital Management added most to Lowe's Companies in Q2 2022, an estimated $69.4M increase.
- Laurion Capital Management's biggest Q2 2022 reduction was T-Mobile US, cutting an estimated $161M.
- Laurion Capital Management fully exited International Flavors & Fragrances in Q2 2022, selling an estimated $284M.
- Laurion Capital Management's ten largest holdings make up 39% of its $6.47B portfolio in Q2 2022.
- Laurion Capital Management opened 244 new positions and closed 303 in Q2 2022.
- Laurion Capital Management's portfolio value fell 21% quarter-over-quarter to $6.47B.
Based on Laurion Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.